Academic pharmacist Nataly Martini provides key information on Helicobacter pylori pathophysiology, diagnosis and evidence-based treatment strategies to enhance patient outcomes
Reducing gout inequities with preventive treatment

Gout highlights significant health inequalities in New Zealand. Māori and Pacific peoples face higher genetic risk, earlier onset and greater severity, with more frequent pain and complications. Clinical writer Noni Richards explains how early detection and preventive treatment are essential to reduce this burden.
Kia ora and welcome to Pharmacy Today Kaitiaki Rongoā O Te Wā
Not a subscriber? Unlock this article by subscribing here.
1. Health Quality & Safety Commission. Atlas of Healthcare Variation: Gout. 10 January 2024.
2. Bryant L. CLASStime: Beyond medicines for gout. Pharmacy Today, 1 October 2021.
3. National Institute for Health and Care Excellence. Gout: diagnosis and management. 9 June 2022.
4. New Zealand Formulary. NZF v150; 1 December 2024.
5. BPACnz. Managing gout in primary care: Part 2 - Controlling gout with long-term urate-lowering treatment. 2 August 2021.
6. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020;72(6):744–60.
7. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64(8):2529–36.
8. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76(1):29–42.